pemetrexed (Alimta, LY231514, Rolazar, Tifolar)
Jump to navigation
Jump to search
Introduction
Tradename: Alimta (FDA-approved in 2004)
Indications
- mesothelioma
- advanced non-small cell lung cancer[2]
- induction therapy in combination with cisplatin
- maintenance therapy unless component of induction therapy [NGC, NICE]*
- not for maintenance therapy of lung squamous carcinoma[2]
* NICE withdraws guideline 'Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer.' Dec 2016
Mechanism of action
Notes
Manufacturer: Lily
More general terms
References
- ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 2.2 Lim MY Non-Small Cell Lung Cancer: 5 Management Challenges. Medscape. Nov 30, 2016 http://reference.medscape.com/features/slideshow/non-small-cell-lung-cancer